title: [Prognostic factors of invasive non-Hodgkin's lymphoma].
abstract: OBJECTIVE
  There is heterogeneity in non-Hodgkin's lymphoma. The purpose of this study is to investigate the prognostic factors of invasive non-Hodgkin's lymphoma.
  
  
  METHODS
  From June 2002 to June 2006, 137 patients with invasive non-Hodgkin's lymphoma were treated by regular regimen consisting of radiotherapy and chemotherapy. The clinical data including prognostic factors was analyzed by SPSS 10.0.
  
  
  RESULTS
  After treated with chemotherapy and radiotherapy, 35 (25.5%) patients achieved CR, 67 (48.9%) PR, 6 (4.3%) SD, 29 (21.2%) PD, ORR (objective response rate) of this series was 74.5%. The overall 4-year survival rate was 70.8%. The PFS (prognosis free survival) was 42.7%. Multivariate analysis using Cox model indicated that clinical stage III-IV, PS score > or = 2, more than 2 external nodal involvement were closely correlated with overall survival.
  
  
  CONCLUSIONS
  The overall survival of invasive non-Hodgkin's lymphoma treated with present combined therapy regimen has been improved greatly. However, further investigation is still needed for exploring more effective individualized treatment regimen.
authors.affiliation: Department of Oncology, Cancer Hospital, Fudan University, Shanghai 200032, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Yu
authors.forename: Xiao-Nan
authors.initials: XN
authors.lastname: Hong
authors.forename: Jin
authors.initials: J
authors.lastname: Li
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Peng
authors.forename: Lan
authors.initials: L
authors.lastname: Ye
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000706:statistics & numerical data; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D012074:Remission Induction; D012189:Retrospective Studies; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone